Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer-Reference-Cited by-同舟云学术

Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer

Published:2019-02-25 Issue:4 Volume:52 Page:198-208
ISSN:1860-1480
Container-title:Medical Molecular Morphology
language:en
Short-container-title:Med Mol Morphol

Author:

Sakaue Takahiko,Koga Hironori,Iwamoto Hideki,Nakamura Toru,Ikezono Yu,Abe Mitsuhiko,Wada Fumitaka,Masuda Atsutaka,Tanaka Toshimitsu,Fukahori Masaru,Ushijima Tomoyuki,Mihara Yuutarou,Naitou Yoshiki,Okabe Yoshinobu,Kakuma Tatsuyuki,Ohta Keisuke,Nakamura Kei-ichiro,Torimura Takuji

Funder

The Promotion and Mutual Aid Corporation for Private Schools of Japan (PMAC) Scholarship Fund for Young Researchers

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s00795-019-00218-5/fulltext.html

Reference26 articles.

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921

2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29

3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607–620